FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fibrinogen-like protein 1 (FGL1) drives non-small cell lung cancer (NSCLC) progression. Targeting FGL1 and its regulators Stat3 and KDM4A, or monitoring FGL1 on circulating tumor cells, may improve NSCLC treatment outcomes.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Non-small cell lung cancer (NSCLC) presents a significant global health challenge with high incidence and poor prognosis.
- Improved understanding of NSCLC pathogenesis and identification of novel therapeutic targets are crucial for better patient outcomes.
- Fibrinogen-like protein 1 (FGL1) has emerged as a protein of interest in cancer biology.
Purpose Of The Study
- To elucidate the role of fibrinogen-like protein 1 (FGL1) in the development and progression of non-small cell lung cancer (NSCLC).
- To investigate the underlying molecular mechanisms by which FGL1 influences NSCLC cell behavior.
- To evaluate FGL1 as a potential diagnostic and prognostic biomarker in NSCLC.
Main Methods
- Investigated the effect of FGL1 on NSCLC cell proliferation, migration, and invasion in vitro.
- Utilized molecular techniques to identify transcription factors and epigenetic modifiers regulating FGL1 expression, including Stat3 and Lysine-specific demethylase 4A (KDM4A).
- Analyzed FGL1 expression levels in NSCLC tumor tissues and adjacent non-cancerous tissues, and on circulating tumor cells (CTCs) from NSCLC patients.
Main Results
- Fibrinogen-like protein 1 (FGL1) significantly promotes NSCLC cell proliferation, migration, and invasion.
- Stat3 acts as a transcription factor for FGL1, with its activity enhanced by KDM4A-mediated demethylation of H3K9me3.
- FGL1 expression is elevated in NSCLC tissues and correlates with shorter overall survival; dynamic changes in FGL1 on CTCs predict therapeutic response.
Conclusions
- Fibrinogen-like protein 1 (FGL1) plays a critical role in NSCLC pathogenesis through Stat3 and KDM4A-mediated regulation.
- FGL1 expression levels in tissues and circulating tumor cells (CTCs) serve as potential prognostic and predictive biomarkers for NSCLC.
- Targeting the FGL1 pathway presents a promising therapeutic strategy for NSCLC patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
